Summary of Cancer Treatment (Comprehensive)

Superscript numbers correspond with lists in "Key for Completing Summary of Cancer Treatment Form"

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Demographics** | | | | |
| Name | | | | |
| Sex M F | Date of birth | Race/Ethnicity1 | SS# | COG Reg # |
| Address | | | | Phone |
| Alternate contact | | Relationship | | Phone |

|  |  |  |
| --- | --- | --- |
| **Cancer Diagnosis** | | |
| Diagnosis2 | | |
| Date of diagnosis | Age at diagnosis | Date therapy completed |
| Sites involved/Stage/Diagnostic details | | Laterality Right Left NA |
| Hereditary/Congenital history3 | | |
| Pertinent past medical history | | |
| Institution | MD/APN | Medical record # |
| **Relapse(s)** **Yes** **No *If yes, provide information below*** | | |
| Date of diagnosis | Age at diagnosis | Date therapy completed |
| Sites involved/Stage/Diagnostic details | | Laterality Right Left NA |
| **Subsequent malignant neoplasm(s)** **Yes** **No *If yes, provide information below*** | | |
| Type4 | | |
| Date of diagnosis | Age at diagnosis | Date therapy completed |
| Sites involved/Stage/Diagnostic details | | Laterality Right Left NA |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cancer Treatment Summary** | | | | |
| **Protocol(s)** **Yes** **No *If yes, provide information below*** | | | | |
| Acronym/Number | Title/Description | Initiated | Completed | On-study |
|  |  |  |  |  |
|  |  |  |  |  |
| **Chemotherapy** **Yes** **No *If yes, provide information below*** | | | | |
| Drug name5 | | Route6 | Additional information†,7 | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
|  | |  |  | |
| †**Anthracyclines**: Include cumulative dose in mg/m2 and age at first dose (see section 34 of Guidelines for isotoxic dose conversion);  **Carboplatin**: Indicate if dose was myeloablative  **IV Methotrexate and Cytarabine**: Indicate if “high dose” (any single dose ≥ 1000 mg/m2) or “standard dose” (all single doses < 1000 mg/m2);  **Note**: Cumulative doses, if known, should be recorded for all agents, particularly for alkylators and bleomycin. | | | | |

# Summary of Cancer Treatment (Comprehensive) (cont)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Cancer Treatment Summary (cont)** | | | | | | | | | |
| **Radiation** **Yes** **No *If yes, provide information below*** | | | | | | | | | |
| Site/Field8 | Laterality | Start/Stop dates | Type9 | Fractions | Dose per fraction (Gy)\* | Initial dose (Gy)\* | Boost site10 | Boost dose (Gy)\* | Total dose (including boost) (Gy)\* |
|  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |
| Institution | | | | | Radiation oncologist | | | | |
| \***Note**: To convert cGy or rads to Gy, divide dose by 100 (example: 2400 cGy = 2400 rads = 24 Gy) | | | | | | | | | |
| **Hematopoietic Cell Transplant** **Yes** **No *If yes, provide information below*** | | | | | | | | | |
| Type11 | | Tandem? | | Source12 | | Date of infusion | | Conditioning regimen13 | |
|  | | * Yes No | |  | |  | |  | |
| Institution | | | | | Transplant physician | | | | |
| **Graft-Versus-Host Disease (GVHD) Prophylaxis/Treatment (for transplant patients only)** **Yes** **No *If yes, provide information below*** | | | | | | | | | |
| Type14 | | | | First dose | | | Last dose | | |
|  | | | |  | | |  | | |
|  | | | |  | | |  | | |
| Was the patient ever diagnosed with chronic GVHD? Yes No Does the patient currently have active chronic GHVD? Yes No | | | | | | | | | |
| **Surgery** **Yes** **No *If yes, provide information below*** | | | | | | | | | |
| Procedure15 | | Date | | Site (if applicable) | | Laterality (if applicable) | | Institution/Surgeon | |
|  | |  | |  | |  | |  | |
|  | |  | |  | |  | |  | |
|  | |  | |  | |  | |  | |
|  | |  | |  | |  | |  | |
|  | |  | |  | |  | |  | |
| **Other Therapeutic Modalities** **Yes** **No *If yes, provide information below*** | | | | | | | | | |
| Therapy16 | | | | Route6 | | | Cumulative dose7 (if known) | | |
|  | | | |  | | |  | | |
|  | | | |  | | |  | | |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Additional Clinical Informatio** | **n** | | | | | | |
| **Complications/Late Effects** | Yes | | * **No** | ***If yes, provide information below*** | | | |
| Problem17 | | Date onset | | | Date resolved | Status | |
|  | |  | | |  | * Active | * Resolved |
|  | |  | | |  | * Active | * Resolved |
|  | |  | | |  | * Active | * Resolved |
|  | |  | | |  | * Active | * Resolved |
| **Adverse Drug Reactions/Allergies** | | | * **Yes** **No *If yes, provide information below*** | | | | |
| Drug | | Reaction | | | Date | Status | |
|  | |  | | |  | * Active | * Resolved |
| **Additional Information/Comments** | | | * **Yes** **No *If yes, provide information below*** | | | | |
|  | | | | | | | |

|  |  |
| --- | --- |
| **Summary prepared by**: | **Date prepared**: |
| **Summary updated by**: | **Date updated**: |

Key for Completing Summary of Cancer Treatment (Comprehensive)

|  |
| --- |
| **#1: Race/Ethnicity** |
| Asian |
| Black/African American |
| Caucasian (non-Hispanic/non-Latino) |
| Hispanic or Latino |
| Native American/Alaskan Native |
| Native Hawaiian/Pacific Islander |
| Multi-racial/multi-ethnic |
| Race/ethnicity, other, specify: |
| **#2: Cancer Diagnosis** |
| **Central Nervous System Tumor** |
| Astrocytoma |
| Cerebellar astrocytoma |
| Supratentorial astrocytoma |
| Brainstem glioma |
| Choroid plexus neoplasm |
| Craniopharyngioma |
| Ependymoma |
| Germ cell tumor, intracranial |
| Optic glioma |
| Pineal tumor |
| PNET |
| Cerebellar (medulloblastoma) |
| Supratentorial PNET |
| Spinal cord tumor, intramedullary |
| CNS tumor, other, specify: |
| **Endocrine tumor** |
| Adrenal tumor (non-neuroblastoma) |
| Thyroid tumor |
| Parathyroid tumor |
| Gastroenteropancreatic tumor |
| Multiple endocrine neoplasia syndrome |
| Endocrine tumor, other, specify: |
| **Germ cell tumor (extracranial)** |
| Seminoma |
| Germinoma |
| Dysgerminoma |
| Non-seminomas |
| Yolk sac tumor |
| Embryonal carcinoma |
| Choriocarcinoma |
| Teratoma |
| Mature |
| Immature |
| With malignant transformation |

|  |
| --- |
| **#2: Cancer Diagnosis (cont)** |
| **Germ cell tumor (extracranial) (cont)** |
| Germ cell tumor, other, specify: |
| **Langerhans cell histiocytosis** |
| **Leukemia** |
| Acute lymphoblastic leukemia |
| Acute myeloid leukemia |
| Chronic myeloid leukemia |
| Myelodysplastic syndrome |
| Myeloproliferative disorder |
| Leukemia, other, specify: |
| **Liver tumor** |
| Hepatoblastoma |
| Hepatocellular carcinoma |
| Liver tumor, other, specify: |
| **Lymphoma** |
| Hodgkin lymphoma |
| Non-Hodgkin lymphoma |
| Lymphoblastic lymphoma |
| Burkitt’s lymphoma |
| Large cell lymphoma |
| Anaplastic large cell lymphoma |
| Diffuse large B-cell lymphoma |
| Lymphoma, other, specify: |
| **Nasopharyngeal carcinoma** |
| **Neuroblastoma** |
| Ganglioneuroblastoma |
| **Renal tumor** |
| Wilms tumor |
| Clear cell sarcoma |
| Renal cell carcinoma |
| Renal tumor, other, specify: |
| **Retinoblastoma** |
| **Sarcoma** |
| Ewing’s sarcoma/peripheral PNET |
| Osteogenic sarcoma |
| Rhabdomyosarcoma |
| Soft tissue sarcoma (nonrhabdomyosarcomatous) |
| Alveolar soft part sarcoma |
| Fibrosarcoma |
| Leiomyosarcoma |
| Liposarcoma |
| Malignant fibrous histiocytoma |
| Malignant peripheral nerve sheath tumor |
| Neurofibrosarcoma |

|  |
| --- |
| **#2: Cancer Diagnosis (cont)** |
| **Sarcoma (cont)** |
| Soft tissue sarcoma (nonrhabdomyosarcomatous) (cont) |
| Synovial sarcoma |
| Undifferentiated sarcoma |
| Sarcoma, other, specify: |
| **Skin cancer** |
| Basal cell carcinoma |
| Malignant melanoma |
| Squamous cell carcinoma |
| Skin cancer, other, specify: |
| **Malignancy, other, specify:** |
| **Diagnosis, other, specify:** |
| **#3: Hereditary/Congenital History** |
| Congenital heart disease |
| Congenital disease, other, specify: |
| Hemihypertrophy |
| Neurofibromatosis  Specify: Type I Type II |
| Down syndrome |
| Syndrome, other, specify: |
| Hereditary condition, other, specify: |
| None |
| Unknown |
| **#4: Subsequent Malignancy Diagnosis** |
| **Bladder cancer** |
| **Breast cancer** |
| **Central nervous system tumor** |
| Malignant, specify type and location: |
| Meningioma, specify location: |
| CNS tumor, other, specify type: |
| **Cervical cancer** |
| **Gastrointestinal cancer** |
| Esophageal cancer |
| Stomach cancer |
| Colorectal cancer |
| Hepatocellular carcinoma |
| Pancreatic cancer |
| GI cancer, other, specify: |
| **Leukemia** |
| Acute lymphoblastic leukemia |
| Acute myeloid leukemia |
| Chronic myeloid leukemia |
| Myelodysplastic syndrome |
| Myeloproliferative disorder |

|  |
| --- |
| **#4 Subsequent Malignancy Diagnosis (cont)** |
| **Leukemia (cont)** |
| Leukemia, other, specify: |
| **Lung cancer** |
| **Lymphoma** |
| Hodgkin lymphoma |
| Non-Hodgkin lymphoma |
| Lymphoblastic lymphoma |
| Burkitt lymphoma |
| Large cell lymphoma |
| Post-transplant lymphoproliferative disorder (PTLD) |
| Lymphoma, other, specify: |
| **Peripheral nerve sheath tumor/ Schwannoma/Acoustic neuroma** |
| **Renal cancer** |
| Renal cell carcinoma |
| Clear cell sarcoma |
| Renal cancer, other, specify: |
| **Sarcoma** |
| Ewing’s sarcoma/peripheral PNET |
| Osteogenic sarcoma |
| Rhabdomyosarcoma |
| Soft tissue sarcoma (nonrhabdomyosarcomatous) |
| Undifferentiated sarcoma |
| Sarcoma, other, specify: |
| **Skin cancer** |
| Basal cell carcinoma |
| Malignant melanoma |
| Squamous cell carcinoma |
| **Thyroid cancer** |
| **Malignancy, other, specify:** |
| **None** |
| **Unknown** |
| **#5: Chemotherapy** |
| Asparaginase |
| Bleomycin |
| Busulfan |
| Carboplatin  Myeloablative dose? Yes No |
| Carmustine (BCNU) |
| Chlorambucil |
| Cisplatin |
| Cladribine |
| Clofarabine |

|  |
| --- |
| **#5: Chemotherapy (cont)** |
| Cyclophosphamide |
| Cytarabine  If IV: any single dose ≥ 1000 mg/m2? Yes No |
| Dacarbazine (DTIC) |
| Dactinomycin |
| Daunorubicin |
| Dexamethasone |
| Docetaxel |
| Doxorubicin |
| Epirubicin |
| Etoposide (VP-16) |
| Fludarabine |
| Fluorouracil |
| Gemcitabine |
| Hydrocortisone |
| Hydroxyurea |
| Idarubicin |
| Ifosfamide |
| Imatinib Mesylate |
| Irinotecan |
| Lomustine (CCNU) |
| Mechlorethamine |
| Melphalan |
| Mercaptopurine |
| Methotrexate  If IV: Any single dose ≥ 1000 mg/m2? Yes No |
| Mitoxantrone |
| Oxaliplatin |
| Paclitaxel |
| Prednisone |
| Procarbazine |
| Temozolomide |
| Teniposide (VM-26) |
| Thioguanine (6-TG) |
| Thiotepa |
| Topotecan |
| Trimetrexate |
| Vinorelbine |
| Vinblastine |
| Vincristine |
| Chemotherapy, other, specify: |
| None |
| Unknown |

|  |
| --- |
| **#6: Route** |
| PO |
| IM |
| IV |
| SQ |
| IT |
| IO |
| Route, other, specify: |
| Unknown |
| **#7: Cumulative Dose**  **(** *Note: this is a required field for anthracyclines and optional but suggested for all others* **)** |
| mg/m2 |
| units/m2 |
| mg/kg  (**Note**: computer will multiply mg by 30 and display as mg/m2 ) |
| Not available |
| Not applicable |
| Cumulative dose, other, specify: |
| Unknown |
| **#8: Radiation Site/Field** |
| **Head/Brain** |
| Cranial |
| Orbital/Eye  Specify: Right Left Bilateral |
| Ear/Infratemporal  Specify: Right Left Bilateral |
| Nasopharyngeal |
| Oropharyngeal |
| Waldeyer’s ring |
| Head/brain radiation, other, specify: |
| **Neck** |
| Cervical (neck)  Specify: Right Left Bilateral |
| Supraclavicular  Specify: Right Left Bilateral |
| **Spine** |
| Spine – cervical |
| Spine – thoracic |
| Spine – lumbar |
| Spine – sacral |
| Spine – whole |
| **Axilla**  Specify: Right Left Bilateral |

|  |
| --- |
| **#8: Radiation Site/Field (cont)** |
| **Chest** |
| Chest (thorax) |
| Whole lung  Specify: Right Left Bilateral |
| Mediastinal |
| Chest, other, specify: |
| **Abdomen** |
| Hepatic |
| Renal  Specify: Right Left Bilateral |
| Upper quadrant  Specify: Right Left Bilateral |
| Spleen  Specify: Partial Entire |
| Paraaortic |
| Flank/hemiabdomen Specify: Right Left  Specify: Extended below iliac crest: Yes No |
| **Pelvis** |
| Pelvic |
| Vaginal |
| Prostate |
| Bladder |
| Iliac |
| Inguinal |
| Femoral |
| **Testicular**  Specify: Right Left Bilateral |
| **Extremity** |
| Upper  Specify: Right Left Bilateral Specify: Proximal Distal Entire |
| Lower  Specify: Right Left Bilateral Specify: Proximal Distal Entire |
| **Total Body Irradiation (TBI)** |
| **Combination Fields:** |
| Mantle |
| Mini-mantle |
| Extended mantle |
| Inverted Y |
| Whole abdomen |
| Total lymphoid irradiation (TLI) |
| Subtotal lymphoid irradiation (STLI) |

|  |
| --- |
| **#8: Radiation Site/Field (cont)** |
| **Radiation site/field, other, specify:** |
| **None** |
| **Unknown** |
| **Add comment:** |
| **#9: Radiation Type** |
| Brachytherapy |
| Conformal |
| External beam (conventional) |
| Intensity-modulated radiation therapy (IMRT) |
| Proton beam |
| Stereotactic |
| Radiation type, other, specify: |
| None |
| Unknown |
| **#10: Radiation Boost** |
| Tumor bed, specify location: |
| Radiation boost location, other, specify: |
| None |
| Unknown |
| Add comment: |
| **#11: Hematopoietic Cell Transplant (HCT) – Type** |
| Autologous |
| Matched related |
| Mismatched related |
| Haploidentical related |
| Syngeneic |
| Matched unrelated |
| HCT type, other, specify: |
| Unknown |
| **#12: Hematopoietic Cell Transplant – Source** |
| Bone marrow |
| Peripheral blood stem cells |
| Cord blood |
| HCT source, other, specify: |
| Unknown |
| **#13: Hematopoietic Cell Transplant – Conditioning Regimen** |
| Anti-thymocyte globulin (ATG) |
| Busulfan |
| Carmustine (BCNU) |
| Cyclophosphamide |
| Etoposide |
| Fludarabine |

|  |
| --- |
| **#13: Hematopoietic Cell Transplant (HCT) – Conditioning Regimen (cont)** |
| Melphalan |
| Thiotepa |
| Total body irradiation (TBI) |
| HCT conditioning regimen, other, specify: |
| Unknown |
| **#14: GVHD Prophylaxis/Treatment** |
| Anti-thymocyte globulin (ATG) |
| Cyclosporine |
| Methotrexate |
| Mycophenolate mofetil (MMF) |
| Prednisone |
| Psoralen plus ultraviolet-A radiation (PUVA) |
| Sirolimus |
| Tacrolimus |
| GVHD prophylaxis/treatment, other, specify: |
| None |
| Unknown |
| **#15: Surgery** |
| Amputation, specify site:  Specify: Right Left Bilateral |
| Central venous catheter |
| Cystectomy |
| Enucleation  Specify: Right Left Bilateral |
| Hysterectomy |
| Laparotomy |
| Limb sparing procedure, specify site: Specify: Right Left Bilateral |
| Nephrectomy  Specify: Right Left Bilateral |
| Neurosurgery – brain  Potential to affect hypothalamic-pituitary axis?   * Yes No |
| Neurosurgery – spinal cord |
| Oophoropexy |
| Oophorectomy  Specify: Right Left Bilateral |
| Orchiectomy  Specify: Partial Unilateral Bilateral  If partial or unilateral, specify: Right Left |
| Pelvic surgery |
| Thoracic surgery\* |
| Splenectomy |

|  |
| --- |
| **#15: Surgery (cont)** |
| Thyroidectomy |
| Surgery, other, specify: |
| None |
| Unknown |
| Add comment: |
| \*Thoracic surgery includes: thoracotomy, chest wall surgery, rib resection, pulmonary lobectomy, pulmonary metastasectomy, and pulmonary wedge resection |
| **#16: Other Therapeutic Modalities** |
| **Systemic Radiation** |
| Radioiodine therapy (I-131 thyroid ablation) |
| Systemic Iodine metalodobenzylguanidine (MIBG) (in therapeutic doses) |
| Systemic radiation, other, specify: |
| **Bioimmunotherapy** |
| Hematopoietic growth factors: |
| Granulocyte colony stimulating factor (G-CSF) |
| Erythropoietin |
| Thrombopoietin |
| Interferon: |
| Alpha interferon |
| Gamma interferon |
| Interleukin: |
| IL-2 |
| IL-11 |
| Other, specify: |
| Monoclonal antibody, specify type: |
| Retinoic acid, specify type: |
| Bioimmunotherapy, other, specify: |
| **Other therapeutic modality, specify:** |
| **None** |
| **Unknown** |
| **#17: Complications/Late Effects (by system)** |
| **Auditory** |
| Conductive hearing loss |
| Eustachian tube dysfunction |
| Otosclerosis |
| Sensorineural hearing loss |
| Tinnitus |
| Tympanosclerosis |
| Vertigo |
| Auditory complication, other, specify: |
| **Cardiovascular** |
| Arrhythmia |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Cardiovascular (cont)** |
| Atherosclerotic heart disease |
| Cardiomyopathy |
| Carotid artery disease |
| Congestive heart failure |
| Infection of retained cuff or line tract |
| Myocardial infarction |
| Pericardial fibrosis |
| Pericarditis |
| Post-thrombotic syndrome |
| Subclavian artery disease |
| Subclinical left ventricular dysfunction |
| Thrombosis |
| Valvular disease |
| Vascular insufficiency |
| Cardiovascular complication, other, specify: |
| **Central Nervous System (CNS)** |
| Ataxia |
| Cavernomas |
| Chronic pain, central neuropathic |
| Clinical leukoencephalopathy |
| Dysarthria |
| Dysphagia |
| Hemiparesis |
| Hydrocephalus |
| Movement disorders |
| Moyamoya |
| Neurocognitive deficits |
| Academic fluency |
| Behavioral change |
| Diminished IQ |
| Executive function (planning and organization) |
| Fine motor dexterity |
| Language |
| Learning deficits in math and reading (particularly reading comprehension) |
| Memory (particularly visual, sequencing, temporal memory) |
| Processing speed |
| Sustained attention |
| Visual-motor integration |
| Neurogenic bladder |
| Neurogenic bowel |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Central Nervous System (CNS) (cont)** |
| Occlusive cerebral vasculopathy |
| Paralysis |
| Seizures |
| Shunt malfunction |
| Spasticity |
| Stroke |
| CNS complication, other, specify: |
| **Dental** |
| Dental caries |
| Ectopic molar eruption |
| Enamel dysplasia |
| Malocclusion |
| Microdontia |
| Osteoradionecrosis of the jaw |
| Periodontal disease |
| Root thinning/shortening |
| Salivary gland dysfunction |
| Temporomandibular joint dysfunction |
| Tooth/root agenesis |
| Xerostomia |
| Dental complication, other, specify: |
| **Dermatologic** |
| Altered skin pigmentation |
| Nail dystrophy |
| Permanent alopecia |
| Sclerodermatous changes |
| Skin fibrosis |
| Telangiectasias |
| Vitiligo |
| Dermatologic complication, other, specify: |
| **Endocrine/Metabolic** |
| Central adrenal insufficiency |
| Diabetes insipidus |
| Dyslipidemia |
| Gonadotropin deficiency (LH/FSH deficiency) |
| Growth hormone (GH) deficiency |
| Hyperprolactinemia |
| Hyperthyroidism |
| Hypothyroidism, primary (thyroid gland failure) |
| Hypothyroidism, central/secondary (T4/TSH deficiency) |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Endocrine/Metabolic (cont)** |
| Impaired glucose metabolism/diabetes mellitus |
| Overweight [Body Mass Index (BMI)]  Age 2–20 yrs: BMI for age ≥ 85 – <95%ile Age > 20 yrs: BMI 25 to 29.9 |
| Obesity  Age 2–20 yrs: BMI for age ≥ 95%ile Age > 20 yrs, BMI ≥ 30 |
| Precocious puberty |
| Thyroid nodule |
| Endocrine/metabolic complication, other, specify: |
| **Gastrointestinal/Hepatic** |
| Abdominal adhesions |
| Bowel obstruction |
| Cholelithiasis |
| Chronic enterocolitis |
| Cirrhosis |
| Esophageal stricture |
| Fecal incontinence |
| Fistula |
| Focal nodular hyperplasia |
| Hepatic dysfunction |
| Hepatic fibrosis |
| Iron overload |
| Sinusoidal obstruction syndrome (SOS) [previously known as veno-occlusive disease (VOD)] |
| Strictures |
| Vitamin B12/folate/carotene deficiency |
| Gastrointestinal/hepatic complication, other, specify: |
| **Immune** |
| Asplenia - functional |
| Asplenia - surgical |
| Chronic hepatitis B |
| Chronic hepatitis C |
| Chronic graft-versus-host disease (cGVHD) |
| Chronic infection |
| Chronic sinusitis |
| Decreased B cells |
| HIV infection |
| Hypogammaglobulinemia |
| Secretory IgA deficiency |
| T cell dysfunction |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Immune (cont)** |
| Immune complication, other, specify: |
| **Musculoskeletal** |
| Chronic pain, musculoskeletal |
| Contractures |
| Fibrosis |
| Functional and activity limitations |
| Hypoplasia |
| Impaired cosmesis |
| Increased energy expenditure (related to amputation/limb salvage) |
| Kyphosis |
| Limb length discrepancy |
| Osteonecrosis (avascular necrosis) |
| Prosthetic malfunction  (loosening, non-union, fracture) requiring revision, replacement or amputation |
| Radiation-induced fracture |
| Reduced bone mineral density (BMD) |
| Reduced or uneven growth |
| Residual limb integrity problems |
| Scoliosis |
| Shortened trunk height |
| Musculoskeletal complication, other, specify: |
| **Ocular** |
| Cataract |
| Chronic painful eye |
| Gaze paresis |
| Glaucoma |
| Keratitis |
| Lacrimal duct atrophy |
| Maculopathy |
| Nystagmus |
| Ocular nerve palsy |
| Optic atrophy |
| Optic chiasm neuropathy |
| Orbital hypoplasia |
| Papilledema |
| Papillopathy |
| Poor prosthetic fit (related to enucleation) |
| Retinopathy |
| Telangiectasias |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Ocular (cont)** |
| Xerophthalmia (keratoconjunctivitis sicca) |
| Ocular complication, other, specify: |
| **Peripheral Nervous System (PNS)** |
| Areflexia |
| Chronic pain, peripheral neuropathic |
| Dysesthesias |
| Foot drop |
| Paresthesias |
| Vasospastic attacks (Raynaud's phenomenon) |
| Weakness |
| PNS complication, other, specify: |
| **Psychosocial** |
| Anxiety |
| Dependent living |
| Depression |
| Educational problems |
| Fatigue |
| Limitations in healthcare and insurance access |
| Impaired quality of life |
| Post-traumatic stress |
| Psychological maladjustment |
| Psychosocial disability due to pain |
| Relationship problems |
| Risky behavior  (behaviors known to increase the likelihood of subsequent illness or injury ) |
| Sleep problems |
| Social withdrawal |
| Suicidal ideation |
| Under-employment/Unemployment |
| Psychosocial complication, other, specify: |
| **Pulmonary** |
| Acute respiratory distress syndrome |
| Bronchiectasis |
| Bronchiolitis obliterans |
| Chronic bronchitis |
| Interstitial pneumonitis |
| Obstructive lung disease |
| Pulmonary fibrosis |
| Restrictive lung disease |
| Pulmonary complication, other, specify: |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Reproductive – Female** |
| Adverse pregnancy outcome |
| Delivery complications |
| Fetal malposition |
| Adverse pregnancy outcome (cont) |
| Low-birth weight infant |
| Neonatal death |
| Premature labor |
| Pregnancy complications |
| Spontaneous abortion |
| Breast tissue hypoplasia |
| Dyspareunia |
| Infertility |
| Pelvic adhesions |
| Pelvic floor dysfunction |
| Premature ovarian insufficiency/ premature menopause |
| Psychosexual/sexual dysfunction |
| Puberty - absence |
| Puberty - delayed/arrested |
| Reduced fertility |
| Symptomatic ovarian cysts |
| Uterine vascular insufficiency |
| Vaginal fibrosis/stenosis |
| Vulvar scarring |
| Reproductive – female complication, other, specify: |
| **Reproductive – Male** |
| Anejaculation |
| Azoospermia |
| Ejaculatory dysfunction |
| Erectile dysfunction |
| Infertility |
| Oligospermia |
| Puberty - absence |
| Puberty - delayed/arrested |
| Reduced fertility |
| Retrograde ejaculation |
| Testosterone deficiency/insufficiency |
| Reproductive – male complication, other, specify: |
| **Urinary** |
| Asymptomatic bacteriuria |
| Bladder fibrosis |

|  |
| --- |
| **#17: Complications/Late Effects (by system) (cont)** |
| **Urinary (cont)** |
| Chronic urinary tract infection |
| Dysfunctional voiding |
| Fanconi syndrome |
| Glomerular injury |
| Hemorrhagic cystitis |
| Hydrocele |
| Hydronephrosis |
| Hyperfiltration |
| Hypertension |
| Hypophosphatemic rickets |
| Proteinuria |
| Renal dysfunction |
| Renal insufficiency |
| Renal tubular acidosis |
| Reservoir calculi |
| Spontaneous neobladder perforation |
| Urinary incontinence |
| Urinary tract obstruction |
| Vesicoureteral reflux |
| Urinary complication, other, specify: |
| **Other, specify:** |
| **No late effects identified** |
| **Unknown** |